A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs VBP 926 (Primary)
- Indications Paronychia
- Focus Therapeutic Use
- Sponsors Veloce BioPharma
- 29 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Nov 2018.
- 29 May 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Aug 2018.
- 29 May 2018 Status changed from recruiting to active, no longer recruiting.